Cholangiocarcinoma PDX Models

Identifying robust preclinical models for cholangiocarcinoma is essential for the development of targeted therapies. Patient Derived Xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity. The CrownBio cholangiocarcinoma PDX collection consists several models which will provide an accurate approach to predicting an agents efficacy prior to entering the clinic. More

Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL ID CANCER TYPE SUBTYPE models per page
CC0449 Cholangiocarcinoma ECC VIEW MODEL Details
CC11307 Cholangiocarcinoma ADC VIEW MODEL Details
CC1470 Cholangiocarcinoma ICC VIEW MODEL Details
CC6204 Cholangiocarcinoma ICC VIEW MODEL Details
CC6205 Cholangiocarcinoma ICC VIEW MODEL Details
CC6216 Cholangiocarcinoma NA VIEW MODEL Details
CC6279 Cholangiocarcinoma ICC VIEW MODEL Details
CC6600 Cholangiocarcinoma ICC VIEW MODEL Details
CC6604 Cholangiocarcinoma ICC VIEW MODEL Details
CC6607 Cholangiocarcinoma ICC VIEW MODEL Details